Ninth Circuit Weighs Revival of Allegations Against Allergan Over Dementia Drug Patents

A patent attorney is seeking to persuade the Ninth Circuit to revive False Claims Act (FCA) allegations against Allergan related to dementia drug patents. The attorney argues that the patents were issued fraudulently to impede the entry of generic drugs into the market. This case has been positioned as the type of expert-led FCA claim the government is reportedly interested in pursuing, leveraging the knowledge of professionals to uncover potential fraud. Detailed commentary on this legal battle can be found on Law360.